Summary of Expertise, Experience, Affiliations and Interests for the Expert Advisory Panel on Insulin (EAP-I)

Purpose of the Summary

The following table summarizes the information about expertise or experience, affiliations and interests provided by the Expert Advisory Panel on Insulin members as part of the nominations process. This Summary is made available as part of the Branch’s commitment to be transparent about the membership of its advisory bodies.

Assessment of affiliations and interests prior to each meeting

Prior to each committee meeting, the Health Products and Food Branch assesses members’ affiliations and interests, including direct financial interests, as they may apply to agenda items for discussion. Depending on the nature of the member's affiliations or interests, the Branch, or the chair of the committee in consultation with the Branch, may limit the participation of a member in the meeting or ask them to make a verbal statement of affiliations and interests at the beginning of the meeting. Members’ affiliations and interests are reviewed on an annual basis and updated as required based on changes in the status of their affiliations and interests.

In accordance with the Health Products and Food Branch Review of Regulated Products: Policy on Public Input and Guidance on Advisory Bodies, a person with a direct financial interest in the outcome of a review of a regulated product may be a member of an advisory body whose broader mandate encompasses matters of policy, management, or program development. However, such a member would not be asked to participate in any discussion, formulation of advice, or recommendations to the Branch relating to that review.

Indicated Sector/Perspective and Expertise

Sector/perspective:

• Health professional
• Industry
• Patient/consumer
• Research/academia

Expertise/experience:

• Biological sciences
• Epidemiology
• Health product vigilance
• Human medicine
• Risk assessment/ communication/ management

1. Direct financial interests
   1. Current employment, investments in companies, partnerships, equity, royalties, joint ventures, trusts, real property, stocks, shares or bonds, with the regulated industry
2. Indirect financial interests
   1. Within the past five years, payment from regulated industry for work done or being done, including past employment, contracts or consulting; or financial support including research support, personal education grants, contributions, fellowships, sponsorships, and honoraria¹
   2. Within the past five years, materials, discounted products, gifts, or other benefits, or attendance at meetings where all or part of the travel and accommodation costs were provided by the regulated industry²
   3. Within the last three years, grants or other funding from the regulated industry to any of the organizations where you are currently employed or participate in internal decision making³
3. Intellectual interests
   1. Within the last five years, any formal advice or opinion to industry, a government organization or a non-government organization on a matter of relevance to the EAP-I.
   2. Within the last five years, any published or publicly stated point of view on issues of relevance to the EAP-I mandate.
   3. Current professional or volunteer affiliations such as membership of professional societies, lobbying, public interest or advocacy groups, of relevance to the EAP-I.
4. Other
   1. Any other affiliations and interests or potential circumstances that might give a well-informed member of the public reasonable grounds for concern regarding the integrity and objectivity of your participation in EAP-I

Affiliations and declarations for Expert Advisory Panel on Insulin members have been fully disclosed to, and vetted by Health Canada and were deemed not to pose a conflict to the mandate of the Panel. Privacy issues restrict more specific publication.

Dr. John Dupré (Chair)

Indicated Sector/Perspective and Expertise
Health professional; research; endocrinology and metabolism; internal medicine

Summary of Responses
1a. No; 2a. No; 2b. No; 2c. No; 3a. Yes; 3b. Yes; 3c. Yes; 4a. No

Comments:
Professor of Medicine & Physiology, Scientist at Robarts Research, University of Western Ontario (UWO); Member Division of Endocrinology and Metabolism, Department of Medicine, UWO, London Health Science Centre; Consultant to related industry; Member of professional associations and editorial boards related to diabetes, i.e., Canadian Diabetes Association (CDA), American Diabetes Association; Numerous publications in related field.

Dr. Michael Coughlin

Indicated Sector/Perspective and Expertise
Health professional; research; Ethicist; neuroscience

Summary of Responses
1a. No; 2a. No; 2b. No; 2c. No; 3a. No; 3b. No; 3c. No; 4a. No;

Comments:
Associate Professor, Dept. Psychiatry and Behavioural Neurosciences, McMaster University, and Chair, Tri-Hospital Research Ethics Board, Kitchener/Cambridge. No declared conflicts, affiliations or interests with respect to insulin.

Dr. Robert Ehrlich

Indicated Sector/Perspective and Expertise
Health professional; endocrinology and metabolism; paediatrician

Summary of Responses
1a. No; 2a. No; 2b. No; 2c. No; 3a. No; 3b. No; 3c. Yes; 4a. No

Comments:
Professor Emeritus Dept of Paediatrics, University of Toronto; Paediatric Endocrine Consultant, Medical Director of Paediatric Diabetes Clinic, Toronto; member of professional associations related to diabetes, including Canadian Diabetes Association Clinical and Scientific Section. Numerous publications in diabetes field.

Dr. George Fantus

Indicated Sector/Perspective and Expertise
Health professional; research; endocrinology and metabolism;

Summary of Responses
1a. Yes; 2a. Yes; 2b. No; 2c. Yes; 3a. No; 3b. No; 3c. Yes; 4a. No

Comments:
Division of Endocrinology and Metabolism, Mount Sinai Hospital, Professor of Medicine and Physiology at University of Toronto; Senior Scientist, Toronto General Research Institute; Director of the Core Laboratory, Banting and Best Diabetes Centre. Family member has shares in related industry < $5000 value; received honoraria from related industry until Nov. 2007; Associate Dean of Research in Faculty of Medicine at U of T where faculty receives grants from Novo Nordisk Canada, Eli Lilly Canada & Sanofi Aventis, but not currently himself in receipt of funding from these companies. Member of many societies and associations for diabetes; Numerous publications in insulin and related fields.

Ms. Colleen Fuller

Indicated Sector/Perspective and Expertise
Patient advocate

Summary of Responses
1a. No; 2a. No; 2b. No; 2c. No; 3a. Yes; 3b. Yes; 3c. Yes; 4a. No

Comments:
Co-chair, Society for Diabetes Rights (SDR); co-founder of PharmaWatch Canada. In 2002 participated in a meeting of Healthcare professionals, scientists, government officials and patients in Switzerland to develop strategies to protect the future availability of animal insulin. In 2003 participated in the Parliamentary Standing Committee on Health (Canada) hearings on human biosynthetic and animal insulins. Member of the Health Canada Scientific Advisory Committee on Metabolic and Endocrine Therapies. Publications, numerous newspaper and magazine articles, TV and Radio interviews on use & availability of animal insulins. Member of Women and Health Protection. WHP research supported by funding agreements through HC's Women's Health Contribution Program with the Canadian Women’s Health Network.

Dr. John Hunt

Indicated Sector/Perspective and Expertise
Health professional; endocrinology and metabolism; diabetes clinician

Summary of Responses
1a. No; 2a. No; 2b. No; 2c. No; 3a. No; 3b. Yes; 3c. Yes; 4a. No

Comments:
Associate professor in Clinical Medicine at UBC. Retired 2006. Special interest in clinical insulin therapy. Professional member with SDR; life member CDA; presented to the Standing Committee on Health on human biosynthetic and animal insulins. Numerous publications on diabetes management.

Dr. Earl Silverman

Indicated Sector/Perspective and Expertise
Health professional; research; endocrinology and metabolism

Summary of Responses
1a. No; 2a. No; 2b. No; 2c. No; 3a. No; 3b. No; 3c. No; 4a. No

Comments:
Professor of Paediatrics & Immunology, Department of Paediatrics, University of Toronto. No declared conflicts, affiliations or interests with respect to insulin.

Dr. Ehud Ur

Indicated Sector/Perspective and Expertise
Health professional; research; endocrinology and metabolism

Summary of Responses
1a. No; 2a. Yes; 2b. No; 2c. No; 3a. Yes; 3b. No; 3c. Yes; 4a. No

Comments:
University of British Columbia; Professor of Medicine and Head, Division of Endocrinology, St. Paul's Hospital and Vancouver General Hospital, Vancouver. Current grant and honoraria from regulated industry but not related to the mandate of the Panel. Member of the Health Canada Scientific Advisory Committee on Metabolic and Endocrine Therapies; Member of many societies and associations , including American Diabetes society; active member and past Chair, CDA; considerable research in related field.